These findings demonstrate that stable ectopic expression of CXCR4 and IL10 enhances the therapeutic efficacy of MSCs and supports the development of an optimized MSC-based product capable of inducing an improved long-term protective immune memory in IBD. This evidence concerns the gene IL10 and inflammatory bowel disease.